Document is current
Any future updates will be listed below
-
Authors
Koga, Yusuke
Kitazawa, Koji https://orcid.org/0000-0003-2203-5776
Shinozaki, Gen
Yoshii, Kengo
Hughes, Jun-Wei B.
Yamashita, Yohei
Kojima, Kentaro
Ueno, Morio
Kinoshita, Shigeru
Sotozono, Chie
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (201960725)
T32 NIA training grant (AG052374)
- License Information
-
More Information
Article History
Received: 21 August 2024
Accepted: 15 February 2025
First Online: 30 April 2025
Declarations
:
: Y. Koga, None; K. Kitazawa, Research Grant (Novartis, AMO), Payment or honoraria for seminar (Otsuka, Santen, Wakamoto, AMO, Senju); G. Shinozaki, Support for attending meetings and/or travel (Sumitomo), Patents planned, issued or pending (Non-invasive device for predicting and screening delirium (PCT application no. PCT/US2016/064937 and US provisional patent no. 62/263,325), Prediction of patient outcomes with a novel electroencephalography device (US provisional patent no. 62/829,411), Devices, systems, and method for quantifying neuro-inflammation (US Patent Application No. 63/124,524.)); K. Yoshii, None; J-W. B. Hughes, None; Y. Yamashita, None; K. Kojima, None; M. Ueno, None; S. Kinoshita, Research grant (Santen, Otsuka, Senju, Kowa, HOYA, Oncolys Biopharma, CorneaGen), Honorarium for lecture and consulting (Santen, Otsuka, Senju, Kowa, Alcon, Johnson & Johnson, Novartis, Astellas, Tarsus), Patent license fee (CorneaGen, Aurion Biotech); C. Sotozono, Research Grant (Santen, Alcon, Senju, Otsuka, Nitto Medic, Nitten, Kowa, CorneaGen), Payment or honoraria for seminar (Otsuka, Santen, Senju, Toa).
